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Purpose: S-propargyl-cysteine (SPRC; alternatively known as ZYZ-802) is a novel mod-
ulator of endogenous tissue H2S concentrations with known cardioprotective and anti-
inﬂammatory effects. However, its rapid metabolism and excretion have limited its clinical
application. To overcome these issues, we have developed some novel liposomal carriers to
deliver ZYZ-802 to cells and tissues and have characterized their physicochemical, morpho-
logical and pharmacological properties.
Methods: Two liposomal formulations of ZYZ-802 were prepared by thin-layer hydration and
the morphological characteristics of each liposome system were assessed using a laser particle
size analyzer and transmission electron microscopy. The entrapment efﬁciency and ZYZ-802
release proﬁles were determined following ultraﬁltration centrifugation, dialysis tube and HPLC
measurements. LC-MS/MS was used to evaluate the pharmacokinetic parameters and tissue
distribution proﬁles of each formulation via the measurements of plasma and tissues ZYZ-802
and H2S concentrations. Using an in vivo model of heart failure (HF), the cardio-protective
effects of liposomal carrier were determined by echocardiography, histopathology, Western blot
and the assessment of antioxidant and myocardial ﬁbrosis markers.
Results: Both liposomal formulations improved ZYZ-802 pharmacokinetics and optimized
H2S concentrations in plasma and tissues. Liposomal ZYZ-802 showed enhanced cardiopro-
tective effects in vivo. Importantly, liposomal ZYZ-802 could inhibit myocardial ﬁbrosis via
the inhibition of the TGF-β1/Smad signaling pathway.
Conclusion: The liposomal formulations of ZYZ-802 have enhanced pharmacokinetic and
pharmacological properties in vivo. This work is the ﬁrst report to describe the development
of liposomal formulations to improve the sustained release of H2S within tissues.
Keywords: liposome, S-Propargyl-cysteine, SPRC, ZYZ-802, hydrogen sulﬁde, heart
failure, myocardial ﬁbrosis, TGF-β1/Smad pathway
Introduction
Over the last decade, great strides have been made in our understanding of the biological
andphysiological signiﬁcance of hydrogen sulﬁde gas (H2S) inmammals.
1–3 Importantly,
this molecule is regarded as the third gasotransmitter alongside carbon monoxide and
nitric oxide. In the cells and tissues of our bodies, H2S is produced by the enzymes
cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-mercaptopyruvate
sulfur transferase (3-MST).4 Within the cardiovascular system, H2S production, via the
catabolism of cysteine by the enzyme CSE, is reported to act as a cytoprotectant against
oxidative stress and has distinct functions in inﬂammatory and apoptotic signaling.5,6
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Moreover, roles for H2S gas production in vasorelaxation,
7 the
stimulation of angiogenesis,8–10 and protective functions in
myocardial ischemia,11,12 atherosclerosis,13 anemia,14,15
hypertension,16 hypoxia17 and heart failure18 have been
reported.
Owing to the important roles for this gas in many
physiological processes, a variety of natural and synthetic
donor molecules have been developed to allow for the
manipulation of H2S gas within tissues.
19,20 Of the many
donor molecules described, one of the most widely char-
acterized, is S-propargyl-cysteine (SPRC) alternatively
known as ZYZ-802. ZYZ-802 is a structural analogue of
S-allylcysteine (SAC), a constituent of garlic with known
cardioprotective effects.21 To date, ZYZ-802 has been
shown to be protective in models of hypoxia/reoxygena-
tion (H/R) injury,22 ischemic reperfusion injury,23 in heart
failure (HF)24 and in angiogenesis.25 One of the key
mechanisms responsible for these effects is the ability of
ZYZ-802 to increase the expression and activity of CSE
protein and to increase endogenous H2S concentrations in
animal tissues. Therefore, ZYZ-802 could serve as a useful
tool to allow for the manipulation of H2S gas in vitro and
in vivo. In spite of this, ZYZ-802 suffers from one major
drawback, that of its rapid metabolism and elimination in
animal tissues.26 This fact alone limits any clinical appli-
cation for this molecule and as such new delivery strate-
gies are needed to improve the pharmacokinetic proﬁle of
this molecule.27
Lately, liposomes have been shown as useful delivery
vehicles for drugs with poor physiochemical characteris-
tics like poor solubility or poor pharmacokinetics traits.28
These nanoparticles are formed by the self-assembly of
phospholipid molecules and can be used as carriers for the
delivery of therapeutic molecules.29 The manipulation of
these carrier systems via the incorporation of polymers
such as polyethylene glycol (PEG) or the incorporation
of targeting ligands such as antibody can prolong circula-
tion times, reduced immunogenicity and provide targeted
delivery of drug-like molecules to target tissues. Cationic
liposomes have been used as an excellent delivery carrier
for antitumor drugs, and the cationic charge on the lipo-
somal surface facilitates the intracellular uptake of the
carrier via the electrostatic interaction with the anionic
charge of cancer cell membrane.30 Temperature-sensitive
liposomes have been shown to be effective for tumor-
suppression in association with hyperthermia because of
their superior biodegradability, drug encapsulation capabil-
ity, and sharp response to ambient temperature change.31
Recently, the development of heart-targeted liposomal car-
riers is promising to lower the incidence of heart
diseases.32 Anti-P-selectin conjugated immunoliposomes
containing VEGF could signiﬁcantly improve vasculariza-
tion and cardiac function based on the overexpression of
P-selection in the infarcted myocardium.33 PEGylated
liposomal adenosine showed to enhance the cardioprotec-
tive effects of adenosine against I/R injury and to reduce
its unfavorable hemodynamic effects.34
In this study, we have developed two liposomal carriers of
ZYZ-802 and characterized their physicochemical, morpho-
logical and pharmacological properties. We expected that
these two liposome formulations of ZYZ-802 could realize
sustained release of ZYZ-802 both in vitro and in vivo, which
further could increase the corresponding level of H2S in heart
and improve the cardioprotective effects of ZYZ-802 against
hypoxia. In vivo, one of the optimized liposomal ZYZ-802
was applied to a rat HF model with left coronary artery
ligation, which was supposed to be effective for therapeutic
efﬁcacy based on the in vitro and pharmacokinetic study
result. The TGF-β1/Smad pathway and its downstream mole-
cules were evaluated for the exploration of the anti-
myocardial ﬁbrosis effect of DP-ZYZ-802.
Materials and Methods
Animal
Male Sprague-Dawley rats weighing 200–220 g (8–10
weeks old) were used in our previous studies in speciﬁc
pathogen-free (SPF) facility24,25,27 and were obtained from
the Joint Ventures Sipper-BK Experimental Animal Co
(Shanghai, China) in the current study. Animals were main-
tained under SPF conditions with stable room temperatures
(24±1°C) and humidity levels (50–60%), and a 12 hrs light-
dark cycle. Each polycarbonate animal cages contained six
rats with wooden chips as bedding that was changed daily.
All animals had access to food and water with body weights
were recorded daily throughout the course of all experi-
ments. In each experiment, rats were divided upon arrival
into groups using restricted randomization so that average
body weights were similar between the groups. The animals
were treated humanely, all surgery was performed under
anesthesia of 1.5% inhalational isoﬂurane and all efforts
were made to minimize animal suffering and the animal
numbers. All work involving animals was approved by the
Department of Animal Care and Use Committee of Fudan
University, and all experiments were conducted according to
the Guide for the Care and Use of Laboratory Animals of the
Tran et al Dovepress
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Ministry of National Health and Family Planning of
People’s Republic of China. Animal studies were carried
out in compliance with the current NIH guidelines.35
Chemicals and Reagents
ZYZ-802 was synthesized by our laboratory as pre-
viously described.23 Hydrogenated soy phosphatidylcho-
line (HSPC), cholesterol (Chol), poly (ethylene glycol)
(MW ~2,000 Da)-disteroylphosphatidylethanolamine
(PEG-DSPE) were purchased from NFC (Japan).
Trichloromethane, dicetylphosphate (DP) and stearyla-
mine (SA) were purchased from Sigma-Aldrich (St
Louis, MO, USA).
Design and Preparation of Liposomal
ZYZ-802
Two formulations of liposomal ZYZ-802 were prepared
using thin-layer hydration. Brieﬂy, two liposomal carriers
were synthesized and had the following lipid composition,
HSPC: Chol: DSPE-PEG: SA (molar ratio = 55: 35: 3: 7)
or, HSPC: Chol: DSPE-PEG: DP (molar ratio = 55: 35:
3: 7). Both were dissolved in trichloromethane and these
represented SA-ZYZ-802 and DP-ZYZ-802 respectively.
The organic solvent was removed under vacuum using
a rotary evaporator at 40°C and the homogenous lipid
ﬁlm obtained further dried under a vacuum overnight.
20 mM ZYZ-802 in PBS was added to each lipid ﬁlm in
a 65°C water bath and shaken for 2 hrs to form a liposomal
suspension. Finally, liposomal carriers were prepared via
a high-pressure micro-jet (Nano DeBEE, B.E.E.
International, Inc, USA) maintained at 4°C to form uni-
lamellar liposomal particles containing ZYZ-802 having
a diameter of 200 nm. Thereafter, the liposomes were
dialyzed against PBS for 4 hrs using a Spectra/Por® with
a molecular weight cut-off of 10 KDa (Float-A-Lyzer G2;
Spectrum Laboratories, Inc, USA) to remove any non-
encapsulated ZYZ-802.
Characterization of Liposomal ZYZ-802
An ultraﬁltration centrifugation method was employed to
determine the entrapment efﬁciency (EE) of LP-ZYZ-802.
LP-ZYZ-802 was divided into two 1 mL samples. The ﬁrst
sample was diluted (10 ×) using distilled water in an
ultraﬁltration tube (Slide-A-Lyzer, MWCO: 10KDa;
Thermo Scientiﬁc, USA) and centrifuged at 4000 rpm/
10mins. The bottom liquid was collected and analyzed
by HPLC to determine the concentration of ZYZ-802
with this serving as a measurement reﬂective of the Cfree
fraction. The remaining 1 mL aliquot was diluted (10 ×)
with methanol to rupture the liposomal carriers and the
concentration of ZYZ-802 determined by HPLC. This
sample represented the Ctotal value. Entrapment efﬁciency
was calculated according to the following calculation:
EE% ¼ 100% Ctotal  Cfreeð Þ=Ctotal
Five independent batches of liposome were evaluated
with the mean EE (%) ± standard deviation.
The size distribution of liposomes was determined by
dynamic light scattering (ZEN5600, Malvern Instruments
Limited, UK). Five independent batches of each liposome
formulation were evaluated to calculate the mean diameter
by volume ± standard deviation values. The zeta-potentials
were measured using a ZetaPALS zeta-potential analyzer
(ZEN5600, Malvern Instruments Limited, UK). In brief,
liposomes from ﬁve independently produced batches were
diluted in deionized water. The Smoluchowski model was
used to calculate the zeta-potential for each liposomal carrier
and the results expressed as the mean ± standard deviation.
Keymorphological characteristics for both SA-ZYZ-802 and
DP-ZYZ-802 were observed using a transmission electron
microscope (JEM −2100F, JEM Japan). For the analysis of
liposomes, suspensions were absorbed on to a carbon-coated
copper grid and place upon some ﬁlter paper. The grids were
air-dried, visualized, and photographed. For the stability
studies, ﬁve independent batches of liposome were stored
and sealed in sterile vials at 4°C for 30 and 60 days.
Thereafter, samples were taken out from the vials for char-
acterization including particle size, and entrapment efﬁ-
ciency evaluation. The stability of liposomal ZYZ-802 was
assessed in line with the original values before storage.
For drug release studies, an in vitro model was used to
determine the retention of ZYZ-802 in both liposome
carriers. In essence, LP-ZYZ-802 was dialyzed against
PBS in dialysis tubing (Float-A-Lyzer G2; MWCO 10K,
Spectrum Laboratories, Inc. USA) at room temperature.
Samples remaining in the dialysis tube were collected at
different time points (0, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30 and
36 hrs), and the liposomes ruptured using methanol. The
concentration of ZYZ-802 was then measured in each
fraction using HPLC and the release rates calculated.
Pharmacokinetic Studies
The plasma pharmacokinetic proﬁles of free ZYZ-802, DP-
ZYZ-802 and SA-ZYZ-802 were evaluated in male SPF
Sprague-Dawley rats (8–10 weeks, weighing 200–220g)
Dovepress Tran et al
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and these animals were fasted for 12 hrs before and 3 hrs after
dosing. These animals were weighed and followed a restrict
randomization to ensure the average weights of rats in each
group were similar. In groups of six, rats were intravenously
injected with ZYZ-802 (10 mg/kg body weight) via the tail
vein and the plasma concentrations of ZYZ-802 determined
across the time points (0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30,
36 and 48 hrs) by collecting tail vein blood samples (50 μL).
ZYZ-802 was extracted from the plasma samples and mea-
sured using LC-MS/MS as previously reported.36 In brief,
chromatographic analysis was performed on an Agilent 1200
Series HPLC system (Agilent Technologies, Palo Alto, CA,
USA) equipped with a column (150mm×4.6mm i.d. with 5
µm particles, Shiseido, Japan) which contained C18 bonded
silica particles and sulfonic acid cation-exchange particles.
The mobile phase was composed of acetonitrile/ammonium
acetate buffer (10 mM, pH 4): 30/70 (v/v). The mass spectro-
meter was operated in positive ion mode using an AB 4000Q
TRAP tandem mass spectrometer. Quantiﬁcation was per-
formed by multiple reaction monitoring (MRM) of the tran-
sitions of m/z 160.0→143.0 for SPRC and 178.1→160.9 for
S-butyl-cysteine (IS). Themethodwas validated according to
the Guidelines for Bioanalytical Method Validation of the
Food and Drug Administration (FDA). DAS2.1 (M002-V2.
1, Data Analysis System, DAS for PK, Mathematical
Pharmacology Professional Committee of China, Shanghai,
China). Absolute bioavailability (F) was determined for each
dose according to the following equation: F (%) =AUC0−t
(i.g.)/AUC0−t(i.v.) ×100 (AUC0−t, estimated using linear tra-
pezoidal method). Log-transformed date for Cmax/dose and
AUC0−t/dose were analyzed using one-way ANOVA regres-
sion model to test dose proportionality. Tmax was analyzed
using nonparametric test (Kruskal–Wallis test). Volume of
distribution (Vd) was calculated using the area under the
moment curve following equation: Vd=A/(AUC×Ke).
For tissue distribution studies, rats in groups of six were
intravenously injected with ZYZ-802 (10 mg/kg body
weight) and at separate time points (1, 6, 12 and 24 hrs)
the animals were sacriﬁced using carbon dioxide euthanasia.
Organs including heart, liver, kidney, spleen and lung were
collected and 0.25 g of each organ was homogenized in
1 mL of saline and then centrifuged at 3000 rpm/4°C/
10mins. A 20 μL of the supernatant was added to 1 mL of
methanol with the internal standard added (0.44 μg/mL
Fmoc-S-butyl-cysteine). Following vortexing (1 min) the
samples were then centrifuged at 12,000 rpm/4°C/10mins.
A 5 μL aliquot of each extract was then used for LC-MS/MS
analysis to conﬁrm the presence of ZYZ-802.
H2S Measurement
H2S levels modulated by ZYZ-802, DP-ZYZ-802 and SA-
ZYZ-802 were evaluated in the plasma and tissues of treated
animals. In brief, animals were fasted for 12 hrs before and 3
hrs after dosing. In groups of six, rats were intravenously
injected with ZYZ-802 or liposomal carrier (10 mg/kg body
weight) via the tail vein and at 1, 6, 12 and 24 hrs the animals
were sacriﬁced using carbon dioxide euthanasia. Blood sam-
ples were collected in EDTA-containing tubes and tissues
including heart, liver, kidney, spleen and lung removed.
Samples were further processed according to previously
reported methods and H2S levels determined as described
by Tan et al37 In brief, chromatography was performed using
a Waters Acquity UPLC (Milford, MA, USA) equipped with
a Kinetex XB-C18 column (50 mm × 2.1 mm, 2.6 μm) from
Phenomenex (Torrance, CA, USA). The components were
eluted by a gradient of A) 0.08% formic acid in water and B)
acetonitrile and the ﬂow rate was 0.6 mL/min. The Waters
Acquity UPLC was coupled with an AB Sciex API 5500
triple quadrupole mass spectrometer (Foster City, CA,
Canada). Positive ionizationmode for electrospray ionization
source was used for detection. Data were collected in
selected reaction monitoring (SRM) mode using transitions
of m/z 415.1 → m/z 223.3 (SDB) and m/z 419.1 → m/z
227.3 (36S-labeled SDB). The data were acquired and pro-
cessed using AB Sciex Analyst 1.5 Software (Foster City,
CA, Canada). The method was validated for different biolo-
gical matrices, including plasma, tissues (i.e., heart, liver,
kidney), and cultured cells. Validation parameters such as
selectivity, linearity, precision, accuracy, recovery, matrix
effects, and stability were investigated according to the
Guidelines for Bioanalytical Method Validation of the Food
and Drug Administration (FDA). The concentrations of H2
S were determined using a standard curve.
Animal Model and Experiments
A heart failure model was used as previously reported.12,38
In brief, animals were anesthetized and connected to an
electrocardiograph (ECG) recorder and a tracheal intuba-
tion performed. Once the animals were breathing passively,
the chest between the third and fourth rib was opened and
the left coronary artery was ligated permanently at the left
anterior descending (LAD) with a silk thread. Sham surgery
was performed but without ligation for the sham control
group. An immediate color change in the ischemic area and
an ST-segment elevation as determined using electrocardio-
gram were considered as successful ligation. The chest was
Tran et al Dovepress
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closed and povidone iodine was used to sterilize the skin.
After 24 hrs, except the Sham group treated with saline
(1 mL/kg/day) (n=8), the surviving animals were randomly
divided into four groups with average body weights were
similar between the groups: HF treated with saline (1 mL/
kg/day) (n=12), HF treated with DP-LP (1 mL/kg/day)
(n=12), HF treated with ZYZ-802 (10 mg/kg/day) (n=10),
HF treated with DP-ZYZ-802 (10 mg/kg/day) (n=10). All
treatments were randomly applied via intravenous tail vein
injection for 6 weeks. Following this procedure, cardiac
parameters were assessed using echocardiography
(Vevo770, Visual Sonic Inc., Toronto, Canada; with a 716
probe). Hereafter, the animals were sacriﬁced using carbon
dioxide euthanasia, heart/body weight ratio and infarct size
determination, and histopathology analysis of myocardial
ﬁbrosis as previously described.12 Afterward, samples of 6
rats from each group were randomly selected for the sub-
sequent experiments. All measurements and data analyst
were performed by a person blinded to the treatment group.
Biomarker Analysis
Antioxidant and stress markers including the measurement
of superoxide dismutase (SOD), glutathione (GSH), mal-
ondialdehyde (MDA), TGF-β1 and brain natriuretic peptide
(BNP) were measured in serum samples. All measurements
were conducted six times independently using commer-
cially available kits in accordance with the manufacturer’s
instruction (A001-3-2, A006-2-1, A003-1-2, H034 and
H166; Nanjing Jiancheng Bioengineering Institute,
Nanjing, China) and data are presented as fold change of
Sham group to control for unwanted sources of variation.
Immunoblot Analysis
Tissue lysates were prepared using RIPA lysis buffer
(Beyotime Biotechnology, Shanghai, China) containing pro-
tease and phosphatase inhibitors. Protein concentrations were
determined by BCA protein assay kit (Beyotime Institute of
Biotechnology, Shanghai, China). Immunoblot was used to
determine protein expression levels using standard procedures.
Following the transfer of proteins onto polyvinylidene ﬂuoride
(PVDF) membranes (Millipore, Billerica, MA) and blocked
with 5% BSA (Sigma-Aldrich) for 1 h at 37°C, these were
incubated with the respective primary antibodies at 4°C over-
night. After several washes with TBST buffer (0.1% Tween
20) the membranes were then incubated with an appropriate
peroxidase-conjugated secondary antibody (HRP ﬂuorescent
Goat anti-Mouse IgG1 (Thermo Fisher Scientiﬁc, Inc, NY,
USA; Catalogue number: A-21124, Alexa Fluor 568,
1:10000) or Goat anti-Rabbit IgG (Cell Signaling
Technology, Inc, NY, USA; Catalogue number: A-11008,
Alexa Fluor 488, 1:10000)) for 2 hr at 37°C. The primary
antibodies used were anti-CSE (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) mouse mAb (Catalogue number:sc-
374249; IgG1, 1:1000); anti-Smad2 (Proteintech Group, Inc,
IL, USA) rabbit polyclonal antibody (Catalogue number:
12570-1-AP, IgG, 1:1000); anti-Smad3 (Proteintech Group,
Inc, IL, USA) rabbit polyclonal antibody (Catalogue number:
25494-1-AP, IgG, 1:1000); anti-phospho-Smad2 (Cell
Signaling Technology, Inc, MA, USA) rabbit mAb
(Catalogue number: 8828, Ser465/467, IgG, 1:1000); anti-
phospho-Smad3 (Cell Signaling Technology, Inc, MA, USA)
rabbit mAb (Catalogue number: 9520, Ser423/425, IgG,
1:1000); anti-CTGF (Proteintech Group, Inc, IL, USA) rabbit
polyclonal antibody (Catalogue number: 23936-1-AP, IgG,
1:1000); anti-SMA (Proteintech Group, Inc, IL, USA) rabbit
polyclonal antibody (Catalogue number: 55135-1-ig, IgG,
1:1000); anti-MMP2 (Proteintech Group, Inc, IL, USA)
mouse mAb (Catalogue number: 66366-1-AP, IgG1,
1:1000); anti-MMP9 (Cell Signaling Technology, Inc, MA,
USA) rabbit mAb (Catalogue number: 13667, IgG, 1:1000)
anti-Collagen I (Proteintech Group, Inc, IL, USA) rabbit poly-
clonal antibody (Catalogue number: 14695-1-AP, IgG,
1:1000); anti-GAPDH (Proteintech Group, Inc, IL, USA)
rabbit polyclonal antibody (Catalogue number: 10494-1-AP,
IgG, 1:1000). Primary Antibodies were diluted in dilution
buffer (1% BSA, 0.1% gelatin, 0.5% Triton X-100, 0.05%
sodium azide, 0.01M PBS, pH 7.2–7.4) (Beyotime
Biotechnology, Shanghai, China). Each ﬁnal antibody solution
was re-used two or three times within 2 weeks. The mem-
branes were probed using an Odyssey two-color infrared laser
imaging system (LI-COR Biosciences, Lincoln, NE, USA).
The experiments were duplicated to ensure the reliability of
the result in six independent sets of data, and representative
pictures are shown. The relative intensities of individual pro-
tein bands were calculated using ImageJ (NIH) by a person
blinded to the treatment group and data are presented as fold
change of Sham group to control for unwanted sources of
variation.
Statistical Analysis
Results are presented as the mean ± SEM. All experiments
have n of at least 5 of group size or were performed at least
ﬁve times independently. Statistical analyses were performed
by GraphPad Prism 5.01 software (GraphPad Software, Inc.,
San Diego, CA, USA). Statistical differences among the
multiple groups were examined using one-way analysis of
Dovepress Tran et al
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variance (ANOVA) or by two-tailed Student’s t-test.
Statistical signiﬁcance was deﬁned as P<0.05.
Results
Characterization of Liposomal ZYZ-802
Two liposomal formulations of ZYZ-802 composed of i) DP-
ZYZ-802, (HSPC: Chol: DSPE-PEG: DP; molar ratio =55:
35: 3: 7) and, ii) SA-ZYZ-802, (HSPC: Chol: DSPE-PEG:
SA; molar ratio =55: 35: 3: 7) were evaluated in the current
work. The physiochemical characteristics of empty liposomes
(SA-LP and DP-LP) and carriers containing ZYZ-802 are
shown in Table 1 and Figure 1. These nanoparticles were
found to maintain a similar spherical particle size of 200nm in
diameter when loaded with ZYZ-802, indicating that ZYZ-
802 did not alter the particle size of the formulated liposomes.
Moreover, the calculated entrapment efﬁciency showed that
the incorporation of ZYZ-802 into each liposome was com-
parable in each formulation. Additional stability studies con-
ducted at 0, 30 and 60 days indicated that DP-ZYZ-802 was
more stable than that of SA-ZYZ-802 with no signiﬁcant
change in particle size and entrapment efﬁciency across this
time course measured with the methods described in the
section of materials and methods accordingly (Table 2).
As shown in Figure 2A, the kinetics of ZYZ-802 release
from liposomes was determined in vitro following HPLC
analysis. Free ZYZ-802 was rapidly released from the dialysis
tubing within 30 min. In contrast, both SA-ZYZ-802 and DP-
ZYZ-802 demonstrated the prolonged release of ZYZ-802
over 36 hr. This demonstrated that the retention of ZYZ-802
within the liposomal nanoparticles provides a means for the
slow-release of ZYZ-802. Based on these observations, the
pharmacokinetic proﬁles for individual liposomes were
assessed in vivo.
Pharmacokinetic Proﬁles of Liposomal
ZYZ-802
The pharmacokinetic proﬁles of both SA-ZYZ-802 and
DP-ZYZ-802 were determined in animals following the
administration of 10 mg/kg of each liposomal formulation
or free ZYZ-802. As shown in Figure 2B, the free drug as
well as the two liposomal formulations of ZYZ-802 exhib-
ited simple monoexponential decline over the measured
time period. The plasma concentration proﬁles for each
drug were interpreted using a non-compartment method
(see Table S1). The maximum observed concentration
values (Cmax) of SA-ZYZ-802 and DP-ZYZ-802 were
approximately 5 times higher than that of free ZYZ-802.
These results showing that ZYZ-802 was retained within
the liposomal formulations rather than been distributed to
other tissues. Notably, the terminal phase half-lives for
both SA-ZYZ-802 and DP-ZYZ-802 were extended as
compared with free ZYZ-802. Indeed, based on the area
under the curve data (AUC0-∞), both SA-ZYZ-802 and
DP-ZYZ-802 signiﬁcantly increased the total drug expo-
sure times in animal tissues. However, comparing the two
different liposomal formulations, DP-ZYZ-802 was
deemed to be superior to SA-ZYZ-802 and had a longer
half-life, smaller volume of distribution, reduced apparent
clearance and a greater AUC.
Both the liposomal formulations of ZYZ-802 were
found to increase the concentration of ZYZ-802 at each
time point within the heart, liver, kidney, spleen and lung
tissues (Figure 2C–G and Table S2). Maximal accumulation
of both liposomal formulations occurred within 1 hr and
declined thereafter at the time points 6, 12 and 24 hrs. In
each instance, both formulations appeared to be retained in
tissues to a greater extent than that of free ZYZ-802.
Additional analyses were also conducted to assess whether
the tissue distribution rates of each liposomal formulation
corresponded to an increase in tissue and plasma H2
S concentrations. As shown in Figure 3A and Table S3,
plasma H2S level for both SA-ZYZ-802 and DP-ZYZ-802
was steadily maintained over several hours as compared to
ZYZ-802 alone. Similar patterns of H2S production in the
tissues of animals were also found as shown in Figure 3B–F
and Table S4. The two liposomal formulations signiﬁcantly
generated more H2S than free ZYZ-802 did in all of the
tissues at all time points measured. In particular, the H2
S produced in the heart was the most, while the H2
Table 1 The Physical Properties of Liposomal Formulations Containing ZYZ-802. Five Independent Batches of Each Liposome
Formulation Were Evaluated to Calculate the Mean Diameter, Zeta-Potential and Entrapment Efﬁciency
Physical Properties DP-ZYZ-802 SA-ZYZ-802 DP-LP SA-LP
Entrapping efﬁciency (%) 32.4±3.8 30.3±6.1 / /
Vesicle diameter (nm) 190.5±5.7 205.4±4.6 191.3±3.9 209.4±2.0
Zeta potential (mV) −47.2±3.8 45.6±1.7 −45.1±2.5 48.7±4.3
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S produced in spleen and lung was far lower than any or
other tissues.
Since the production of H2S in tissue seemed contra-
dictory in accordance with ZYZ-802 distribution in tissues,
we assumed it should be due to the high expression levels of
CSE in heart but not in other tissues. Thus, the expression
levels of CSE in different tissues were measured by immu-
noblots, intending to explain the apparent contradiction.
Western blot analysis of tissue extracts indicated that H2
S production rates in tissues corresponded with the protein
expression levels of the enzyme CSE (Figure 3G–H). The
expression of CSE protein in heart was the highest, which
was 23%, 30%, 60% and 60% higher than that in kidney,
liver, spleen and lung, respectively.
DP-ZYZ-802 is Cardioprotective in an
in vivo Model of Heart Failure
DP-ZYZ-802 was selected for additional analyses based
on its pharmacokinetic proﬁles and stability.
Histopathology analysis showed that DP-ZYZ-802 miti-
gated myocardial ﬁbrosis in heart failure by reducing
collagen ﬁber distribution in HF animals as compared to
ZYZ-802 alone (Figure 4A). Triphenyltetrazolium chlor-
ide (TTC) staining showed that DP-ZYZ-802 signiﬁcantly
reduced the infarct size in the left ventricle as compared
with that of the HF group and was superior to the ZYZ-
802 treatment groups (Figure 4B and C). Moreover, the
heart/body weight ratio (HW/BW) indicated that DP-ZYZ
-802 signiﬁcantly reduced this ratio (Figure 4D). Typically
in this model of heart failure, cardiac functions decrease
following left anterior descending coronary artery ligation.
As shown in Figure 5 (Supplementary Table S5), at 6
weeks post-surgery, the ejection fraction (EF) values and
fractional shortening (FS) values of animals in the HF
group were notably lower than those in the Sham group.
These effects were reversed in the DP-ZYZ-802 treatment
group. In addition, DP-ZYZ-802 signiﬁcantly reduced left
ventricular volume in systole (LVs) and left ventricular
internal dimension in systole (LVIDs) and improved left
ventricular anterior wall in systole (LVAWs) and left ven-
tricular posterior wall in systole (LVPWs) as compared
with the HF group. Taken together the echocardiography
results indicated that DP-ZYZ-802 preserved changes in
LVs, LVIDs, LVAWs and LVPWs that are caused during
heart failure.
Parallel experiments were conducted to determine
possible changes in the serum levels of both BNP and
TGF-β1. In this instance, both biomarkers were raised
approximately 2.9–5.0 fold as compared to the Sham
group following the induction of HF. Moreover, DP-
ZYZ-802 could effectively restore the levels of both
these markers compared with the untreated group
(Figure 6). Similarly, in HF group, GSH and SOD activ-
ity levels were diminished while lipid peroxidation was
elevated. Again in the DP-ZYZ-802 group, GSH and
SOD levels were preserved and lipid peroxidation inhib-
ited in animal tissues.
The Effect of DP-ZYZ-802 on TGF-β1/
Smad Pathway
Western blot was used to determine protein expression
levels of TGF-β1/Smad signaling pathway. As shown in
Figure 1 Characterization of liposomal ZYZ-802. Morphological analysis of DP-ZYZ-802 and SA-ZYZ-802 was performed by using Transmission electron micrograph.
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Figure 7B–I, the low protein expression levels of TGF-β1/
Smad related proteins in the sham control group are indi-
cative of healthy perfused tissues with no evidence of
myocardial ﬁbrosis. In contrast, following the induction
of HF a signiﬁcant increase in the protein expressions'
levels of p-Smad2/3, α-SMA, MMP-2/9, CTGF and col-
lagen I were seen; these ﬁndings have been consistent with
the noted increase in serum TGF-β1 levels. In contrast, the
administration of DP-ZYZ-802 effectively reduced the
expression of myocardial ﬁbrosis-related proteins. As
Table 2 Liposomal Formulations Stability. Five Independent Batches of Liposome Were Stored and Sealed in Sterile Vials at 4°C for 30
and 60 Days. Thereafter, Samples were Taken Out from the vials for Characterization Including Particle Size, and Entrapment Efﬁciency
Evaluation. The stability of liposomal ZYZ-802 Was Assessed in Line with the Original Values Before Storage
Time Period (Day) DP-ZYZ-802 SA-ZYZ-802
Vesicle Diameter (nm) Entrapping Efﬁciency (%) Vesicle Diameter (nm) Entrapping Efﬁciency (%)
0 189.0±5.4 30.5±2.0 205.7±5.9 28.6±1.3
30 193.7±4.7 28.9±1.8 252.3±47.4 26.1±1.3*
60 196.1±6.4 27.8±2.0 266.2±47.9* 23.1±0.9*
Notes: *P<0.05 vs 0 Day, calculated by two-tailed Student’s t-test
Figure 2 SA-ZYZ-802 and DP-ZYZ-802 prolong the release of ZYZ-802 as determined in vitro and in vivo. (A) Representative in vitro release proﬁles of ZYZ-802, DP-
ZYZ-802 and SA-ZYZ-802 measured by HPLC (n=3). (B) Plasma concentration–time curves after intravenous injection of ZYZ-802, DP-ZYZ-802 and SA-ZYZ-802 in rats
(n=6). (C–G) Heart, liver, kidney, spleen and lung tissues ZYZ-802 concentrations at different time points (1, 6, 12 and 24 hrs) after intravenous injection of ZYZ-802, DP-
ZYZ-802 and SA-ZYZ-802 in rats (n=6). ZYZ-802 plasma and tissue concentration were measured using LC-MS/MS. The graph is representative of six rats per group and
the results are expressed as mean ± SEM. Detailed data are listed in Supplementary Tables S1 and S2.
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compared with the HF group, DP-ZYZ-802 reduced the
protein expression levels by 37% for p-Smad2, 32% for
p-Smad3, 30% for CTGF, 36% for α-SMA, 30% for
MMP-2, 27% for MMP-9 and 24% for collagen I.
The Effect of DP-ZYZ-802 on CSE
Expression in Rats
The expression of CSE in the rat heart was analyzed by
immunoblots 6 weeks after myocardial infarction.
Compared with the HF group, the administration of DP-
ZYZ-802 and ZYZ-802 both greatly promoted the expres-
sion of CSE (Figure 7A). The CSE expressions of DP-ZYZ
-802 group and ZYZ-802 group were 1.7 times and 1.6
times as high as that of HF group or DP-LP group, respec-
tively. More signiﬁcantly, DP-ZYZ-802 was more effective
than ZYZ-802 to elevate CSE expression in HF rats with
23% more expression.
Discussion
It is now widely recognized that H2S gas plays important
roles in many physiological and pathophysiological
processes.39–44 Indeed, in many disease models, tissue
H2S levels are seen to be reduced, and importantly, replen-
ishment of this gas using donor molecules can improve
disease outcomes.45–48 ZYZ-802 is a compound that can
alter plasma H2S levels and the tissue expression of CSE
protein.22,23,49 However, unfavorable clearance of ZYZ-
802 in animals hinders its use.26,27 Therefore, to overcome
these limitations and to improve the pharmacokinetic pro-
ﬁle of this molecule we have designed and tested two novel
Figure 3 Liposome formulations increased plasma and tissue H2S concentrations and the protein expression of CSE. (A) Plasma H2S concentrations at different time points
after intravenous injection of ZYZ-802, DP-ZYZ-802 and SA-ZYZ-802 in rats, respectively (n=6). The graph is representative of six rats per group and the results are
expressed as mean ± SEM. (B–F) Heart, liver, kidney, spleen and lung tissues H2S concentrations at different time points after intravenous injection of ZYZ-802, DP-ZYZ-
802 and SA-ZYZ-802 in rats, respectively (n=6). After intravenous injection, the concentrations of H2S gas at 1 hr, 6 hrs, 12 hrs and 24 hrs were measured using LC-MS/MS,
respectively. The graph is representative of six rats per group and the results are expressed as mean ± SEM. (G–H). Finally, the expression of CSE in tissue of animals
determined by Western blot (n=6), the blot and bar graph are representative of six independent experiments. Data are presented as fold change of the heart. Results are
expressed as mean ± SEM. &P<0.05 vs heart. Detailed data are listed in Supplementary Tables S3 and S4.
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liposomal carrier systems, DP-ZYZ-802 and SA-ZYZ-802.
To date, it is widely known that the liposomal delivery of
drugs can increase their circulation time, reduce toxicity
and enhance the therapeutic efﬁciency of molecules, and is
therefore an attractive system to be employed in drug
development.50
Traditionally, it is believed that only free drugs not bound to
proteins are biologically active. Therefore, the currently avail-
ablemethodsmeasuring the total drug concentration to explain
the pharmacokinetics and efﬁcacy of nano-liposomal drugs is
insufﬁcient or even could bring misunderstanding, though it
remains a difﬁcult problem to be conquered in the research
Figure 4 DP-ZYZ-802 decreased cardiac ﬁbrosis, infarct size and HW/BW. (A) High-magniﬁcation microphotograph of Masson-stained sections from border zones in
indicated treatment groups. (B) Photograph of infarct size which was determined following staining with 1% triphenyltetrazolium chloride (TTC). (C) The infarct sizes were
calculated by the ratio of the infarct area and left ventricle. The picture and bar graph are representative of eight rats per group (n=8) and the results are expressed as mean
± SEM. (D) Representative statistical analysis of HW/BW with Sham (n=8), HF (n=12), ZYZ-802 (n=10) and DP-ZYZ-802 (n=10). Results are expressed as mean ± SEM,
#P<0.05 vs Sham, *P<0.05 vs HF, &P<0.05 vs ZYZ-802.
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ﬁeld of liposomal drug delivery to distinguish the amount of
free drug and capsulated drug in vivo. In many cases, the
enhancement of efﬁcacy of liposomal drugs seems to be due
to the direct distribution of the active drug to the target organ by
bypassing the unbound form of the active drug. The unbound
drug concentrations in encapsulated and unencapsulated form
in certain tissue, respectively, should be both useful to provide
more accurate information of the PK/PD relationship of the
liposomal drugs. Thus, for liposomal drug PK study, in addi-
tion tomeasuring the encapsulated and released drug, it should
be more meaningful to distinguish the concentration of drug
that is released but not bound to either plasma proteins or tissue
proteins. It also has been recommended by the FDA and other
agencies as one of the contents for evaluating nano-
formulations by determining the drug releasedwithout binding
to proteins.51
In this study, LC-MS/MS method was used to evaluate the
pharmacokinetic parameters and tissue distribution proﬁles of
each liposome formulation via the measurements of plasma
and tissues ZYZ-802. This method with high sensitivity and
speciﬁcity has been successfully used to measure ZYZ-802
levels in a broad range of biological matrices, such as
blood, plasma, tissues, cells, and enzymes, across different
species.26,36 Pharmacokinetic study showed the accumulation
of ZYZ-802 in the kidney and liver. Recent studies suggest that
ﬂuorescence dyes are excellent tools to investigate the drug
microbiodistribution in the tissue after i.v. administration.
However, ZYZ-802 labeled with ﬂuorescence dyes suffer
from limitations, ﬁrstly, due to their aromatic structure, these
molecules are generally poorly soluble in aqueous medium,
thus poorly bioavailable. This limited water solubility issue is
particularly difﬁcult for the preparation of liposomes.
Fluorescence dyes may be degraded or will separate from
ZYZ-802 during the preparation of liposomes. For most appli-
cations, the stability of dye in tissues is the primary concern.
After administration, ﬂuorescence dyesmay be separated from
ZYZ-802, in this case, the dye concentration in tissues will
include ﬂuorescent dye of free and conjugated with ZYZ-802,
but may not contain free ZYZ-802 in these tissues. Moreover,
dye has narrow excitation bands, small Stokes shifts,
Figure 5 DP-ZYZ-802 improves cardiac function after myocardial infarction. (A–F) Echocardiographic recordings obtained from a short-axis mid-ventrical view of hearts
indicating the changes in the ejection fraction (EF), and fractional shortening (FS), left ventricular internal dimension in systole (LVIDs), left ventricular internal dimension in
systole (LVAWs), left ventricular posterior wall in systole (LVPWs) and left ventricular volume in systole (LVs) (n=6). The bar graph is representative of six rats per group and
the results are expressed as mean ± SEM, #P<0.05 vs Sham, *P<0.05 vs HF, &P<0.05 vs ZYZ-802.
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autoﬂuorescence, broad ﬂuorescence bands, bleaching and
dark states, complication of handling. From these limitations,
dyemolecules are less attractive for durable, sensitive, accurate
quantiﬁcation and multiplexed imaging.
We have measured the total amount of drugs for liposomal
ZYZ-802 pharmacokinetics study and tissue distribution,
which is a shortcoming of the current study. Although previous
studies have found that the binding rate of ZYZ-802 to plasma
proteins is very low in all measured species including human,
rat and dog, factors in vivo including physiological, formula-
tion, pathological effects may still affect the binding of ZYZ-
802 to plasma and tissue proteins.26 Instead, rather than assum-
ing the PKproﬁles andPK/PD relationship ofZYZ-802 simply
relying on its protein binding feature from in vitro study, it
remains to be necessary to measure the concentrations of both
ZYZ-802 that is not directly bound to protein and that is
encapsulated when appropriate methods are available in the
future.
With this in mind, this study is the ﬁrst to describe the use
of liposomal formulations to deliver an H2S donor molecule to
tissues in order to deliver deﬁned amounts of this gas. In this
regard, both liposomal formulations of ZYZ-802 successfully
extended the distribution of ZYZ-802 within tissues including
the heart, liver, spleen, kidney and lung. Interestingly, liposo-
mal formulation of ZYZ-802 resulted in the highest amount of
ZYZ-802 distributing to the spleen. Generally, systematically
administered liposomes are mostly taken up by the reticuloen-
dothelial system (RES), which contributes to the major accu-
mulate of liposomal particles in tissue such as spleen and liver
because RES is more abundant in these tissues.52 In contrast,
the corresponding produced H2S was far lower than expected
in spleen but it was the highest amount in heart and kidney.
Meanwhile, the concentrations of H2S in spleen and lung did
not alter too much at 1hr and 6hrs. The phenomenon seemed
somewhat controversy to the ZYZ-802 distribution in tissue,
but it was not. Sharing the similar structure of cysteine, ZYZ-
802 could increase the expression of CSE and promote the
production of H2S in accordance with our previous study.
25
Recent studies indicated that CSE mainly distributed in heart,
kidney and liver but not spleen or lung. Our immunoblot study
also demonstrated that CSE mostly expressed in heart and
kidney whereas barely expresses in spleen or lung. Although
Figure 6 DP-ZYZ-802 alters antioxidant defences and improves cardiac function in myocardial infarction. (A–B) Serum levels of BNP and TGF-β1 6 weeks after infarction
induction (n=6), and (C–E) serum levels of SOD, GSH and MDA in all groups 6 weeks after infarction (n=6). Data are presented as fold change of Sham group. The bar graph
is representative of six independent experiments and the results are expressed as mean ± SEM; #P<0.05 vs Sham, *P<0.05 vs HF, &P<0.05 vs ZYZ-802.
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the liposomes increased ZYZ-802 concentration in spleen and
lung, the amount of CSE in these two organs was relatively
saturated, thus leading to the little difference in
H2S production at 1hr and 6hrs. Likewise, the amounts of
ZYZ-802 in lung and liver were comparable to those in heart
and kidney, but heart and kidney obviously generated more
H2S.
In accordance with the stability of ZYZ-802 and its poor
bioavailability, we intended to improve it from the aspect of
liposomal formulation, and our ﬁnal goal is to solve the
problem for its clinical use. However, before it can realize
clinical use, there are still several difﬁculties to be conquered.
Firstly, ordinary liposomes composed of phospholipids and
cholesterol are pretty sensitive to the destruction of gastric
acid and gastrointestinal contents, thus they are easy to be
inactivated with low bioavailability. That is also why most
liposomes could only be administered intravenously which is
not very friendly to chronic diseases. Secondly, lacking of the
cell membrane protein skeleton in the phospholipid bilayer
membrane, the physical stability is comparatively poor. Since
inside the liposomes is liquid, the phospholipid bilayer mem-
brane is highly ﬂuid, and the liposomes are easily deformed
and broken both in vitro and in vivo. Additionally, the encap-
sulation efﬁciency of the drug in liposomes is generally low,
Figure 7 DP-ZYZ-802 increases the expression of the H2S biosynthetic enzymes CSE in heart tissues and alleviates cardiac ﬁbrosis after myocardial infarction. (A) The
expression of CSE in the heart following Western blot analysis (n=6). (B–I) Western blot and statistically analysis indicate that DP-ZYZ-802 decreases the expression of
p-Smad2/3, CTGF, Collagen I, α-SMA, MMP-2 and MMP-9 in hearts following myocardial infarction (n=6). The blot and bar graph are representative of six independent
experiments. Data are presented as fold change of Sham group. Results are expressed as mean ± SEM, #P<0.05 vs Sham, *P<0.05 vs HF, &P<0.05 vs ZYZ-802.
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especially for small water-soluble molecules. Finally, the cost
for preparing liposomes is generally higher, and the prepara-
tion process and quality control are more complicated.53,54
Although liposomal drugs have such disadvantages as men-
tioned above, it is still being explored as an efﬁcient drug
delivery approach, especially for potential targeting delivery.
Compared with previously developed release formulations for
ZYZ-802 vs the Eudragit ® RS30D carrier system,24,27 these
newer liposomal formulations were a much-improved system.
Indeed, in this work, in vitro release studies have shown that
both liposome formulations have a longer time of release of
around 50% of ZYZ-802 and retention time than RS30D.
Moreover, nanoparticles delivery system liposome formula-
tion can reach the diseased tissues and taken up by cells more
easily than conventional formulation. SA-ZYZ-802 and DP-
ZYZ-802 were composed of phospholipid, cholesterol and
PEG which are able to integrate with a biological system
without eliciting immune response or any negative effects in
addition to prolong the circulation of ZYZ-802. Referring to
the tissue distribution study, there is still a limitation for the
off-target delivery of ZYZ-802 to other tissues. Based on the
above points, the creation of liposomal formulation of ZYZ-
802 has established a platform for potential speciﬁcally target-
ing the delivery of ZYZ-802 to cardiovascular systems if
choosing a proper ligand such as antibodies targeting to vas-
cular endothelial growth factor (VEGF). Since antibody/
ligand-targeted liposomal drug delivery systems have shown
improved delivery efﬁciency and reduced off-target
effects,55,56 the utilization of DP-ZYZ-802 or SA-ZYZ-802
for further targeting therapeutic study in cardiovascular dis-
ease on the basis of this study should be of great interest, and
which is not achievable by the previously reported controlled
release RS30D formulation.
The presence of charged groups such as dicetyl phosphate
and stearylamine on the liposome surface provides charge to
the vesicles, which enhances entrapment efﬁciency and steric
repulsion leading to improved stability. Our study ﬁnds that
DP-ZYZ-802 is more stable than SA-ZYZ-802 because dice-
tyl phosphate was more effectively integrate into the phos-
pholipid bilayer membrane of liposome than stearylamine.
Furthermore, dicetyl phosphate has long alkyl-chains, result-
ing in slow drug release, with long lag times. Further char-
acterization of DP-ZYZ-802 showed it to have a more
favorable pharmacokinetic proﬁle when measured in plasma
and in tissues. As such, subsequent studies have focussed on
the use of this carrier in the models of heart failure. Initial
in vitro analysis found that DP-ZYZ-802 was cytoprotective
in rat embryonic cardiomyocyte cell exposed to hypoxic
stress. In this instance, DP-ZYZ-802 preserved cell viability
more effectively than SA-ZYZ-802 and ZYZ-802 alone (data
not shown). For these reasons, the therapeutic efﬁcacy of DP-
ZYZ-802 was further assessed in an in vivo heart failure
model. Heart failure is a common syndrome caused by car-
diac dysfunction associated with myocardial structural
changes due to myocardial infarction (MI), cardiomyopathy
and high blood pressure.56,57 As compared to our previous
studies using ZYZ-802, DP-ZYZ-802 was more effective at
reducing the HW/BW ratio and in preventing heart ﬁbrosis.
Moreover, DP-ZYZ-802 treatment enhanced cardiac indexes
including EF, LV, LVID, LVAW and LVPW. Analysis of
biomarkers of heart failure showed these were altered in
animals receiving DP-ZYZ-802 treatment. Indeed, biomar-
kers related to cardiac functions, as demonstrated in the
preservation of stress markers like SOD and GSH were
preserved in tissues following DP-ZYZ-802 treatment,
respectively. In addition, in this work, it was also found that
plasma levels of BNP were increased following HF induc-
tion. Plasma BNP concentrations correlate with the severity
of HF and the measurement of serum BNP in patients after
myocardial infarction can not only be linked to the infarct
size and left ventricular systolic dysfunction, but as a marker
of left ventricular remodeling and mortality risk.59,60 In our
study, serumBNP levels increased in HF and were reduced in
the DP-ZYZ-802 group. This has been consistent with the
echocardiographic ﬁndings and the observed cardioprotec-
tive effects of DP-ZYZ-802 in our model of heart failure.
Our previous work has demonstrated that ZYZ-802 inhi-
bits TGF-β1 signaling in chronic kidney disease.61 As such,
we next explored whether the cardioprotective effects of
ZYZ-802 in HF were due to a similar effect. A large body
of evidence indicates that oxidative stress is a common med-
iator of cardiac damage following HF and that oxidative
stress can induce transforming growth factor (TGF-β1) sig-
naling. TGF-β1 is a multifunctional protein that can increase
extracellular matrix deposition, can promote the expression
of cardiac ﬁbroblasts and increases the synthesis of type I and
III collagens.61–63 Initially, experiments conﬁrmed that DP-
ZYZ-802 induces CSE protein expression within the hearts
of treated animals. Next, it was shown that TGF-β1 was
elevated 6 weeks post-MI induction in our model and that
DP-ZYZ-802 suppressed TGF-β1. In the same model, it was
also shown using Masson staining speciﬁed that DP-ZYZ
-802 efﬁciently reduced the degree of myocardial ﬁbrosis
followingMI. Interestingly, recent studies have indicated that
exogenous H2S can suppress the expression of MMP-2 and
MMP-9, via the inhibition of the TGF-β1/Smad signaling
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pathway.65 Since DP-ZYZ-802 can increase endogenous H2
S gas concentration, it seems reasonable that this molecule is
also involved in the suppression of TGF-β1/Smad signaling
in our model. Indeed, raised H2S concentrations in both
plasma and tissues, coupled with the increased expression
of CSE protein in heart tissues would suggest this to be the
case. Accordingly, the expressions of ﬁbrotic proteins in
cardiac tissues were determined using Western blot analysis.
Consequently, following heart failure, phosphorylated
Samd2/3 was found to increase in the heart of rats following
MI induction along with the expressions of MMP-2/9,
CTGF, α-SMA and collagen I. It could be due to the elevated
levels of TGF-β1 thereby activated TGF-β1/Smad. The
administration of DP-ZYZ-802 was able to attenuate the
expression of p-Smad2/3, and thereby reduce the expression
of MMP-2/9, CTGF, α-SMA and collagen I. This ﬁnding
demonstrates that one of the mechanisms by which DP-ZYZ
-802 prevents myocardial ﬁbrosis is likely via an H2S, TGF-
β1/Smad mediated mechanism.
Conclusion
In summary, liposomal formulations have been designed to
deliver the cardioprotective agent, ZYZ-802. These car-
riers offered prolonged maintenance of the endogenous H2
S concentration within animal tissues and had improved
pharmacokinetic properties as compared to the parental
molecule. In vivo, DP-ZYZ-802 had improved tissue dis-
tribution and caused a signiﬁcant increase and sustained
the production of H2S gas in heart tissues. Moreover, it
was also demonstrated that DP-ZYZ-802 had signiﬁcant
therapeutic effects in HF and could inhibit the TGF-β1/
Smad signaling pathway. Further preclinical studies based
on the use of the identiﬁed formulations are warranted.
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